Abstract. Cyclooxygenase (COX)-2 and its products, including PGE 2 , are key inflammatory mediators. In this study, we have assessed the pharmacological characteristics of BAI, a 3-aminoindazole derivative and a novel cyclin-dependent kinase (CDK) inhibitor, for regulation of COX-2 expression induced by interleukin (IL)-1β in A549 human airway cells. Treatment with BAI strongly inhibited IL-1β-induced expression of COX-2 at both the protein and mRNA levels. Results of luciferase experiments also revealed that BAI treatment reduced IL-1β-induced COX-2 promoter activity. Distinctly, treatment with BAI did not affect IL-1β-induced phosphorylation of extracellular signal-regulated protein kinase-1/2 (ERK-1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal protein kinase-1/2 (JNK-1/2) and proteolysis of IκB-α, an inhibitor of nuclear factor (NF)-κB, but inhibited IL-1β-induced phosphorylation of histone H1, a target for phosphorylation by CDKs. siRNA transfection experiments demonstrated that knockdown of CDK2 and CDK4 led to a slight reduction of IL-1β-induced histone H1 phosphorylation but had no effect on IL-1β-induced COX-2 expression. Interestingly, additional cell culture experiments showed the ability of BAI to repress the PMA-induced COX-2 expression in A549 cells and serum-dependent COX-2 expression in NCI-H292 cells, a human laryngeal cell line. Collectively, these results demonstrate firstly that BAI downregulates IL-1β-induced COX-2 expression through transcriptional repression, which appears to be independent of CDK2, CDK4, MAPKs and NF-κB, in A549 cells. It is suggested that BAI may be a potential candidate for treatment of the airway inflammatory diseases where COX-2 overexpression is problematic.
Introduction
Cyclooxygenase (COX), also referred to as prostaglandin (PG) H synthase, is the rate-limiting enzyme in the biosynthesis of PGs and related eicosanoids from arachidonic acid metabolism (1) . Physiologically, PGs are involved in the inflammatory response, bone development, wound healing, and reproductive system. However, excessive PGs play a pathogenic role in inflammatory and neoplastic diseases (2, 3) .
In eukaryotic cells, COX is expressed in two isoforms, COX-1 and COX-2. While COX-1 is constitutively expressed in most cells and the COX-1-derived PGs are involved in the maintenance of physiological functions, COX-2 is inducible by pro-inflammatory cytokines, tumor promoters, mitogens, and growth factors in many cell types, including monocytes, fibroblasts, and endothelial cells (1) (2) (3) (4) (5) . Importantly, evidence that non-steroidal anti-inflammatory drugs or compounds that inhibit COX-2 lessen major inflammatory symptoms including fever and pain strongly suggests the role of COX-2 in inflammation (6) . Expression of COX-2 gene is controlled at the transcriptional, post-transcriptional, and/or translational level. For example, transcription of COX-2 is induced in cells following the exposure of exogenous stimuli, which leads to activation of intracellular signaling pathways that in turn modulate the activity of transcription factors and hence stimulate the COX-2 promoter (7). Multiple cis-acting elements within the COX-2 promoter, such as cyclic AMP responsive element, activator protein-1, nuclear factor (NF)-interleukin (IL)-6, and NF-κB, are found to be critical for the COX-2 transcriptional induction (8, 9) . In addition, post-transcriptional COX-2 RNA nuclear export and COX-2 mRNA stabilization have shown to be necessary for maximal COX-2 induction (10-13). Regulation of cellular COX-2 protein levels by protein degradation has also been reported (14, 15) . COX-2 protein N-glycosylation at a co-translational step is also suggested to be critical for the protein stability, localization, and activity (15) (16) (17) (18) (19) . There are also many reports indicating that activities of many intracellular signaling proteins, including extracellular signal-regulated protein kinase-1/2 (ERK-1/2), p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal BAI, a 3-aminoindazole derivative, inhibits interleukin-1β-induced expression of cyclooxygenase-2 in A549 human airway cells protein kinase-1/2 (JNK-1/2), and protein kinase B (PKB) are necessary for the transcriptional, post-transcriptional, and/or translational upregulation of COX-2 expression (20) (21) (22) (23) (24) .
In a previous study, we synthesized a chemical compound,
6 -isothiazolidin-2-yl)-1H-indazol-3-yl)acetamide (BAI), one of the 3-aminoindazole derivatives, as a novel cyclin-dependent kinase (CDK) inhibitor (25) and reported that BAI inhibits proliferation and induces apoptosis via activation of caspases in head and neck cancer cells (26) , suggesting its anticancer activity. To gain insight into the BAI's anti-inflammatory potential, in this study, we evaluated the effect of BAI on IL-1β-mediated induction of COX-2 expression in A549 human airway cells and determined the possible molecular and cellular mechanisms involved.
Materials and methods
Materials. RPMI-1640 medium, fetal bovine serum (FBS), penicillin, and streptomycin were purchased from Welgene (Daegu, Korea). Antibodies of phospho-ERK-1/2 (p-ERK-1/2), total ERK-1/2 (T-ERK-1/2), phospho-JNK-1/2 (p-JNK-1/2), total JNK-1/2 (T-JNK-1/2), phospho-p38 MAPK (p-p38 MAPK), total p38 MAPK (T-p38 MAPK), phospho-PKB (p-PKB), and total PKB (T-PKB) were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-COX-2 rabbit polyclonal antibody was purchased from Cayman Chemicals (Ann Arbor, MI, USA). Anti-rabbit or mouse secondary horseradish peroxidase antibodies were bought from Amersham Biosciences (Amersham, UK). RNAzol-B reagent was purchased from Tel-Test (Houston, TX, USA). Lipofectamine Plus reagents were purchased from Invitrogen (Carlsbad, CA, USA). Enzyme-linked chemiluminescence (ECL) Western detection reagents were purchased from Thermo Scientific (Waltham, MA, USA). An antibody for phospho-histone H1 (p-histone H1) and nitrocellulose membranes were acquired from Millipore (Rockford, IL, USA). IL-1β was purchased from R&D Systems (Minneapolis, MN, USA). Antibodies of CDK2 and CDK4 and siRNAs of scrambled, CDK2, and CDK4 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The Bradford reagent was purchased from Bio-Rad (Hercules, CA, USA). Other reagents, including PMA, were purchased from Sigma (St. Louis, MO, USA).
Cell culture. Human airway cells, A549 (lung) or NCI-H292 (laryngeal), were maintained at 37˚C in a humidified condition of 95% air and 5% CO 2 in RPMI supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Preparation of whole cell lysates. After treatment at the indicated times or conditions, A549 cells or NCI-H292 cells were washed with ice-cold phosphate-buffered saline (PBS) supplemented with 1 mM Na 3 VO 4 and 1 mM NaF, and lysed with a modified RIPA buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.25% sodium deoxycholate, 1% Triton X-100, 1% Nonidet P-40, 1 mM EDTA and 1 mM EGTA, proteinase inhibitor cocktail (1X)]. After centrifugation at 12,000 rpm for 20 min at 4˚C, the supernatant was collected and the protein concentration was determined with Bradford reagent (Bio-Rad, Mississauga, ON, Canada) using bovine serum albumin as the standard.
Western blot analysis. Equal amounts of protein (40 µg/lane) were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane. The membrane was washed with Tris-buffered saline (TBS) (10 mM Tris, 150 mM NaCl) containing 0.05% Tween-20 (TBST) and blocked in TBST supplemented with 5% non-fat dried milk. The membrane was further incubated with primary antibodies against COX-2 (1:2,000), p-histone H1 (1:2,000), CDK2 (1:2,000), CDK4 (1:2,000), p-JNK-1/2 (1:2,000), T-JNK-1/2 (1:2,000), p-ERK-1/2 (1:2,000), T-ERK-1/2 (1:2,000), p-p38 MAPK (1:2,000), T-p38 MAPK (1:2,000), IκB-α (1:2,000) or actin (1:10,000). The membrane was subsequently incubated with the appropriate secondary antibodies coupled to horseradish peroxidase and developed by ECL Western detection reagents.
Reverse transcription-polymerase chain reaction (RT-PCR).
After treatments at the indicated times or conditions, total cellular RNA was isolated from the conditioned cells using RNAzol-B reagent according to the manufacturer's instructions. Five micrograms of total-RNA were reverse transcribed using 8 µl of M-MLV RT 5X buffer, 3 µl of 10 mM dNTPs, 0.45 µl of 10,000 U RNAse inhibitor, 0.3 µl of 50,000 U M-MLV reverse transcriptase (Promega, Madison, WI), and 1.5 µl of 50 pM oligo(dT) (Bioneer, Chungbuk, Korea) in 40 µl volume. Single stranded cDNA was then amplified by PCR using 4 µl of 5X green Go Taq Flexi buffer, 0.4 µl of 10 mM dNTPs, 0.1 µl of 500 U Taq polymerase, 1.2 µl of 25 mM MgCl 2 (Promega), and 0.4 µl of each 20 pM of specific sense and antisense primer of COX-2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The PCR products were analyzed on 1.2% agarose gels. The primer sequences used by PCR were as follows: COX-2, forward, 5'-CCG CGT CAG TAT CAA CTG CG-3' and reverse 5'-CAA TCA TCA GGC ACA GGA GG-3'; GAPDH, forward, 5'-CGT CTT CAC CAC CAT GGA GA-3' and reverse 5'-CGG CCA TCA CGC CAC ACT TT-3' . The PCR conditions applied were: COX-2, 25 cycles of denaturation at 94˚C for 30 sec, annealing at 59˚C for 30 sec, and extension at 72˚C for 30 sec; GAPDH, 25 cycles of denaturation at 94˚C for 30 sec, annealing at 56˚C for 30 sec, and extension at 72˚C for 30 sec, respectively. GAPDH was used as an internal control to evaluate the relative expression of COX-2.
Analysis of COX-2 mRNA stability. A549 cells were initially grown in the absence or presence of IL-1β for 6 h to highly induce cellular levels of COX-2 mRNA. Cells were then treated with IL-1β alone or IL-1β plus BAI for 10, 30, 45 or 60 min in the presence of ActD, a transcription inhibitor, to block ongoing transcription. Total-RNA was isolated and subjected to COX-2 or GAPDH RT-PCR at each time point to determine the mRNA amounts of each gene that remained in the cells.
Analysis of COX-2 protein stability. A549 cells were initially grown in the absence or presence of IL-1β for 6 h to highly induce cellular levels of COX-2 protein. Cells were then treated with IL-1β alone or IL-1β plus BAI for 2, 4 or 8 h in the absence or presence of CHX, a translation inhibitor, to block ongoing translation. At each time, whole cell lysate was prepared and subjected to immunoblot analysis for COX-2 or actin to determine the amounts of each protein remaining in the cells.
Luciferase sssay. A549 cells grown in 24-well plates were transfected for 24 h with a luciferase DNA construct containing a COX-2 promoter. Cells were treated with or without IL-1β in the absence or presence of BAI for additional 6 h. Cell lysates were prepared and assayed with the luciferase assay system (Promega) using a TD 20/20 lumino-meter (Turner Designs Instruments).
siRNA transfection. A549 cells were plated at 2x10 6 cells/ well in 6-well plates. After overnight incubation, cells were transfected with control siRNA (80 nM) or siRNAs of CDK2 (40 nM) and CDK4 (40 nM) using Lipofectamine Plus reagents. At 48 h post-transfection, the transfected cells were treated without or with IL-1β in the absence or presence of BAI for additional 6 h. Cell lysates were then prepared and analyzed by Western blotting to determine expression of CDK2, CDK4, COX-2 or actin protein.
Statistical analysis.
Results are expressed as means ± standard error (SE). The significance of the differences was determined by one-way ANOVA. Differences were considered significant at P-value <0.05. (Fig. 1B, lanes 1-8) .
Results

BAI inhibits COX
RT-PCR experiments were next performed to evaluate the effect of BAI on the expression of COX-2 mRNA induced by IL-1β. As shown in Fig. 1C , compared with control (lane 1), the exposure of IL-1β for 6 h into A549 cells largely increased the expression of COX-2 mRNA (lane 3). However, BAI treatment also inhibited IL-1β-induced COX-2 mRNA expression in a concentration-dependent fashion (lanes 4-8). Expression of control GAPDH mRNA remained constant in A549 cells treated without or with IL-1β for 6 h in the absence or presence of BAI at the doses tested (Fig. 1C, lanes 1-8) . Due to strongest inhibitory effect on IL-1β-induced COX-2 protein and mRNA expression levels, the 5 µM dose of BAI was chosen for further studies. Luciferase experiments were next utilized to determine whether BAI-mediated downregulation of COX-2 mRNA was due to inhibition of COX-2 promoter activity. As shown in Fig. 1D , compared with control (column 1), treatment with IL-1β for 6 h stimulated COX-2 promoter-driven luciferase expression in A549 cells (column 3). However, BAI BAI does not influence COX-2 mRNA and protein stability in IL-1β-treated A549 cells. In addition to the transcriptional regulation, COX-2 expression was also affected at the stability of COX-2 mRNA and/or protein. The effect of BAI on the stability of COX-2 mRNA was next determined by ActD chase experiments. As shown in Fig. 2A , when ongoing transcription was blocked in the presence of ActD, the amounts of COX-2 mRNA induced by IL-1β were decreased within 1 h (lanes 2-6), suggesting the intrinsic instability of COX-2 mRNA. BAI treatment, however, did not further accelerate COX-2 mRNA degradation (lanes 7-10); rather BAI treatment at the time of 45 and 60 min seemed to enhance COX-2 mRNA stability. Expression of GAPDH mRNA remained constant in A549 cells treated without or with IL-1β in the absence or presence of BAI at the doses and times tested (Fig. 1A, lanes 1-10) . The effect of BAI on the stability of COX-2 protein was further analyzed by CHX chase experiments. As shown in Fig. 2B when ongoing translation was blocked in the presence of CHX, the amounts of COX-2 protein induced by IL-1β were decreased in a time-dependent manner (lanes 2-5), suggesting that COX-2 protein is also unstable and is degraded within 8 h. However, BAI treatment also did not accelerate COX-2 protein degradation (lanes 6-8). Expression of actin protein was not affected in A549 cells treated without or with IL-1β in the absence or presence of BAI at the doses and times tested (Fig. 2B, lanes 1-8) .
BAI-mediated downregulation of COX-2 expression in IL-1β-treated A549 cells is independent of CDK2 and CDK4.
Considering BAI as a novel CDK inhibitor, we hypothesized that BAI might exert its inhibitory effect on COX-2 expression in IL-1β-treated A549 cells via modulation of CDKs. CDKs are involved in the cell cycle in part by phosphorylating histone H1, a CDK downstream effector (27) . This promptly led us to investigate the effect of BAI on phosphorylation of histone H1 in IL-1β-treated A549 cells. As shown in (Fig. 3B, lanes 1-4) . 4) .
BAI does not interfere with IL-1β signaling to induce phosphorylation of MAPKs and proteolysis of
BAI is also capable of inhibiting phorbol-12-myristate-13-acetate (PMA)-induced COX-2 in A549 cells and serum-dependent expression of COX-2 in NCI-H292 cells.
The specificity of the BAI effects were assessed by examining its effect on the expression of COX-2 induced by PMA, another COX-2 inducer (28), in A549 cells. As shown in Fig. 5A , compared with the control (lane 1), the exposure of IL-1β or PMA into A549 cells stimulated the expression of COX-2 (lane 2 or 3). Apparently, BAI treatment that had a strong repressive effect on IL-1β-induced expression of COX-2 (lane 4) also largely suppressed PMA-induced COX-2 expression in A549 cells (lane 5). Expression of actin remained constant in A549 cells treated without or with IL-1β or PMA in the absence or presence of BAI (Fig. 5A, lanes 1-5) . In a recent study, we demonstrated the serum-dependent induction of COX-2 expression in NCI-H292 cells, a human laryngeal cell line (29) . As shown in Fig. 5B , high COX-2 expression was detected in NCI-H292 cells grown in normal culture media containing only FBS (lane 1). However, BAI treatment strongly inhibited the serum-mediated induction of COX-2 expression in NCI-H292 cells (lane 2). Expression of actin remained constant in NCI-H292 cells treated without or with BAI (Fig. 5B, lane 1 and 2 ). 
Discussion
Chemicals that inhibit COX-2 have the potential to be clinically useful against inflammatory diseases. In this study, we have assessed pharmacological characteristics of BAI, one of 3-aminoindazole derivatives for regulation of COX-2 expression induced by IL-1β in A549 human airway cells. The inflammatory cytokine IL-1β is involved in inflammatory processes by inducing its receptor-mediated expression of many effector proteins, including COX-2. Overexpression of COX-2 is linked to airway inflammatory disorders. COX-2 expression is regulated at the transcriptional, post-transcriptional, and translational level. Thus, the present findings that BAI downregulates COX-2 protein and mRNA expressions (Fig. 1A and B ) and promoter activity (Fig. 1C) , but does not affect the stability of COX-2 mRNA and protein ( Fig. 2A and B) in IL-1β-treated A549 cells strongly indicate that BAI targets COX-2 at the transcriptional level in IL-1β-treated A549 cells. Considering COX-2 transcriptional upregulation by IL-1β is largely associated with activities of a variety of intracellular signaling components and transcription factors (7) (8) (9) 12, 21, 22, 24) , we hypothesized that BAI-mediated COX-2 transcriptional repression might be due to the ability of BAI to interfere with the IL-1β signal to trigger activation of signaling proteins and/or transcription factors responsible for COX-2 transcriptional induction in IL-1β-treated A549 cells.
It has been demonstrated that IL-1β signals to activate multiple intracellular signaling proteins, including ERK-1/2, p38 MAPK, and JNK-1/2, and transcription factors, such as NF-κB, and their activations are critical for IL-1β-mediated induction of COX-2 expression in A549 cells (9, 12, 19, 22) . In resting cells, NF-κB resides in the cytoplasm by interacting with IκB-α, a NF-κB inhibitory protein. However, when cells are exposed to inflammatory cytokines, IκB-α is rapidly (within 1 h) phosphorylated, ubiquitinated, and degraded by the 26S proteasomal complex (30) , thereby enabling NF-κB to localize into the nucleus where NF-κB participates in the transcriptional regulation of many target genes, including COX-2. In the present study, we have shown that BAI does not inhibit the IL-1β signal to induce the phosphorylation of ERK-1/2, p38 MAPK, and JNK-1/2, and proteolysis of IκB-α in A549 cells (Fig. 4) , suggesting the independence of MAPKs and NF-κB pathways in BAI-mediated COX-2 transcriptional repression in IL-1β-treated A549 cells.
The transcriptional regulation of genes is primarily influenced by the structure of chromatin. Chromatin structure is affected by chromatin components or chromatin modifiers, including histone H1 and high-mobility group proteins. Among those, histone H1 is a linker protein involved in the higher-order and compact chromatin structure by interacting with nucleosomes (31) and has been reported to be posttranslationally modified, by phosphorylation, acetylation, and methylation (32, 33) . Of note, there are several reports to indicate that phosphorylation of histone H1 plays an important role in regulating specific gene expression, as demonstrated by that loss of histone H1 causes both upregulation and downregulation of specific gene expression (34, 35) . Of further interest, there are previous studies demonstrating that phosphorylated histone H1 is enriched in transcriptionally active chromatin (36) , histone H1 phosphorylation affects chromatin condensation (37, 38) , and phosphorylation of histone H1 leads to destabilization of the chromatin structure, allowing for access to the chromatin template of factors required for gene expression (39) .
In this study, we have shown the ability of BAI to repress phosphorylation of histone H1 induced by IL-1β in A549 cells (Fig. 3A) , which may, albeit weakly, suggest that inhibition of histone H1 phosphorylation by BAI may cause transcriptionally inactive chromatin and inaccessibility of transcriptional machineries or factors responsible for COX-2 transcriptional stimulation in IL-1β-treated A549 cells. At present, however, precise mechanisms of how BAI induces inhibitions of histone H1 phosphorylation and COX-2 transcriptional inactivation in response to IL-1β signal remain unclear.
There are previous reports to show phosphorylation of histone H1 by CDKs, including CDK2 (40) (41) (42) . There is further evidence of CDK2-dependent COX-2 expression in the IL-1β-treated H358 human non-small cell lung carcinoma cell line under serum starvation conditions, as determined by CDK2 siRNA transfection or treatment with BMS-387082, a potent CDK2 inhibitor (42) . However, the present findings that siRNAmediated knockdown of CDK2 and CDK4 does not greatly affect IL-1β-mediated induction of histone H1 phosphorylation and COX-2 expression in A549 cells (Fig. 3B ) suggest no involvement of these CDKs in IL-1β-induced histone H1 phosphorylation and COX-2 expression in A549 cells. As a CDK inhibitor, BAI is not likely to exert its repressive effects on IL-1β-induced histone H1 phosphorylation and COX-2 expression in A549 cells through modulation of the expression and/or activities of CDK2 and CDK4. BAI was originally synthesized as a CDK2 inhibitor with the IC 50 concentration of 14 nM, based on the investigation of the X-ray structure of CDK2 in association with the docking study with the ATP binding pocket of the protein kinase (25) . It therefore appears that the 5 µM concentration of BAI, which inhibits IL-1β-induced COX-2 expression in A549 cells, is much far above the dose to inhibit CDK2 activity and thus BAI at such a high concentration may inhibit not only CDK2 and other CDKs but also many cellular protein kinases with similar structure and/or the ATP binding pocket of CDK2, which may contribute to the BAI's repressive effect on COX-2 transcription in response to the IL-1β signal. This notion may be strengthened by a recent study demonstrating inhibition of JNK-2 by the aminoindazoles (43), whose structure is similar to BAI herein.
The present study additionally provides experimental evidence that BAI-mediated repression of COX-2 expression is not limited to the IL-1β signaling in A549 cells, which is deduced from that BAI inhibits the PMA-induced COX-2 expression in A549 cells (Fig. 5A ) and the serum-dependent expression of COX-2 in the NCI-H292 human laryngeal cell line (Fig. 5B) .
In conclusion, we demonstrate for the first time the ability of BAI to inhibit the COX-2 expression by transcriptional repression in IL-1β-treated A549 cells. BAI-mediated COX-2 transcriptional repression appears to be independent of MAPKs, NF-κB, CDK2 and CDK4. Considering COX-2 as a key inflammatory mediator, it is suggested that BAI (or its derivatives) may be potential candidates for the treatment of inflammatory diseases in which overexpression of COX-2 is problematic.
